Treatment of Type 1 VWD with Mild Bleeding Phenotype and Baseline VWF Activity Above 0.30 IU/mL Before Minor Mucosal Procedures
Not every patient with von Willebrand disease requires the same degree of haemostatic preparation before a procedure. In a well-defined subgroup — type 1 VWD with relatively preserved VWF activity and a mild bleeding phenotype — the approach to minor mucosal procedures can be deliberately conservative.
Patients with type 1 von Willebrand disease, baseline VWF activity above 0.30 IU/mL, and a mild bleeding phenotype who are scheduled for a minor mucosal procedure. In this population, the evidence supports a targeted haemostatic strategy without routine augmentation of VWF activity levels.
The evidence-based approach for this specific presentation centres on antifibrinolytic therapy used as a standalone measure — avoiding the need to raise VWF activity before the procedure. The full structured regimen, including alternative antifibrinolytic options and tailored considerations for dental and paediatric settings, is available in the complete protocol.
References
DOI: 10.1182/bloodadvances.2020003264.
- The panel suggests giving tranexamic acid alone over increasing VWF activity levels to $0.50 IU/mL with any intervention in patients with type 1 VWD with baseline VWF activity levels of .0.30 IU/mL and a mild bleeding phenotype undergoing minor mucosal procedures (conditional recommendation based on very low certainty in the evidence of effects).
- Although tranexamic acid was the primary antifibrinolytic considered by the panel, we recognize that epsilon-aminocaproic acid is a reasonable alternative, particularly when used as an oral rinse in dental procedures or as a liquid administration in the pediatric population.